Tag: Usnoflast
Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical...
Usnoflast is a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)
Zydus Lifesciences completes Phase II(a) clinical trial of Usnoflast in ALS...
Usnoflast, a novel oral NLRP3 inflammasome inhibitor, shows promising results in reducing neurodegeneration and improving key health markers
Zydus receives WHO’s approval for ‘Usnoflast’ as recommended name for ZYIL1
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus